Irish Examiner view: Alzheimer’s drug brings hope for many

Good news

The trial shows the first time any drug has been able to indicate a change in the trajectory of Alzheimer's.

Amid this week’s sea of troubles, rolling endlessly to the horizon, it was easy to miss the importance of a scientific news item. It was described as an “historic moment” and, given the experience that some of us have, and will have, it is certainly that.

Alzheimer treatment trials carried out jointly by the Tokyo-based company Eisai, and the Cambridge, Massachusetts, pharma giant Biogen show that cognitive decline was 27% less in early-stage patients treated with lecanemab than others who received a placebo.